Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Osteosarcoma Market to Grow Rapidly by 2032, Assesses DelveInsight | Leading Companies - MedPacto, Y-mAbs, QSAM, BioEclipse, Cellectar Biosciences, BioAtla, Salarius, Jazz, Fusion, Sumitomo Pharma Oncology

New York, USA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Osteosarcoma Market to Grow Rapidly by 2032, Assesses DelveInsight | Leading Companies - MedPacto, Y-mAbs, QSAM, BioEclipse, Cellectar Biosciences,...
November 21, 2022 13:00 ET | Source: DelveInsight Business Research LLP

DelveInsight Evaluates a Robust Osteosarcoma Pipeline as 30+ Influential Pharma Players to Set Foot in the Domain

New York, USA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- DelveInsight Evaluates a Robust Osteosarcoma Pipeline as 30+ Influential Pharma Players to Set Foot in the Domain The prevalence of Osteosarcoma has...
October 26, 2022 08:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer

Austin, TX, Oct. 26, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
October 21, 2022 08:51 ET | Source: Allied Market Research

Global Bone Cancer Treatment Market to Reach $1.8 Billion by 2031: Says AMR

Portland, OR, Oct. 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Bone Cancer Treatment Market was estimated at $1.2 billion in 2021 and is...
February 02, 2022 08:30 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Receives Rare Pediatric Disease Designation from FDA for CycloSam in the Treatment of Osteosarcoma

Austin, TX, Feb. 02, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
December 01, 2021 09:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer

Austin, TX, Dec. 01, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
August 18, 2021 09:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Receives Orphan Drug Designation from FDA for CycloSam® in the Treatment of Osteosarcoma

Austin, TX, Aug. 18, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment...
March 09, 2021 07:00 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma

- Treatment of animal osteosarcoma models with dovitinib increased the median survival time by 50 % as compared to control animals. Press release Hørsholm, Denmark (9 March 2021) – Allarity...
November 24, 2020 09:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Issues Letter from New CEO; Presents Opportunities Ahead for Company

Palm Beach, FL, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The recently appointed Chief Executive Officer of QSAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided in the following letter to...